Clinical Study

A Phase 2 Randomized Study Of Efatutazone, An Oral Ppar Agonist, In Combination With Paclitaxel Versus Paclitaxel In Patients With Advanced Anaplastic Thyroid Cancer

Posted Date: Oct 8, 2014

  • Investigator: Nooshin Hashemi Sadraei
  • Co-Investigator: Null Null
  • Specialties: Hematology/Oncology, Oncology, Cancer, Head & Neck Cancer
  • Type of Study: Drug

The purpose of this study is to compare any good and bad effects of using efatutazone along with the usual chemotherapy to using the usual chemotherapy alone.


To Be Eligible For This Study, Patients Must Have Anaplastic Thyroid Cancer Which Cannot Be Removed With Surgery Or Has Spread To Other Areas Of The Body.


Advanced Anaplastic Thyroid Cancer, Thyroid Cancer, A091305, Cancer, Head & Neck, 2014-5243

For More Information:

Uc Cancer Institute

  • Search Clinical Studies

  • Research in the News

    Ride Cincinnati Gives $200,000 in Grants for Breast Cancer Research

    Marlene Harris-Ride Cincinnati has continued its support of UC Cancer Institutescientists with the annual award of five grants to continue promising breastcancer research.